OPG and Nordion employees at Darlington’s recently refurbished Unit 1, which has been modified to produce cobalt-60 isotopes. (Photo: OPG)
Ontario Power Generation in Canada announced that Unit 1 of its Darlington nuclear power plant, which has returned to service from refurbishment, is now producing the medical isotope cobalt-60. During refurbishment activities, OPG made modifications to the unit to allow it to produce Co-60, which is used to sterilize 30 percent of the world’s single-use medical devices, such as syringes, gloves, and implants.
Darlington nuclear power plant. (Photo: OPG)
The Canadian Nuclear Safety Commission (CNSC) has amended Ontario Power Generation’s (OPG) operating license for its Darlington nuclear power station near Clarington, Ontario, allowing the company to produce the medical radioisotope molybdenum-99 using Darlington’s Unit 2 CANDU reactor. OPG subsidiary Laurentis Energy Partners, in conjunction with BWXT Medical, is leading the program to produce Mo-99 at Darlington.
Don Perrie (left), of OPG, and Michael Lefebvre, of Laurentis Energy Partners, examine the He-3 extraction tool installed at Darlington NPP
Laurentis Energy Partners, a subsidiary of Ontario Power Generation (OPG), has launched a new program to produce helium-3. The He-3 will be obtained from tritium stored at OPG’s Darlington nuclear power plant, a four-unit CANDU station located about 100 kilometers east of Toronto.
Darlington houses one of the world’s largest reserves of tritium, which is a by-product of the heavy water used in CANDU reactors.